119 related articles for article (PubMed ID: 8465414)
1. Rationale for OKT3 monoclonal antibody treatment in transplant patients.
Norman DJ
Transplant Proc; 1993 Apr; 25(2 Suppl 1):1-3. PubMed ID: 8465414
[No Abstract] [Full Text] [Related]
2. OKT3 escalating dose regimens provide effective therapy for renal allograft rejection.
Woodle ES; Bruce DS; Josephson M; Cronin D; Newell KA; Millis JM; Piper JB; O'Laughlin R; Thistlethwaite JR
Clin Transplant; 1996 Aug; 10(4):389-95. PubMed ID: 8884115
[TBL] [Abstract][Full Text] [Related]
3. Cytokine-release syndrome: differences between high and low doses of OKT3.
Norman DJ; Kimball JA; Barry JM
Transplant Proc; 1993 Apr; 25(2 Suppl 1):35-8. PubMed ID: 8465420
[No Abstract] [Full Text] [Related]
4. Prolonged neurological disability following OKT3 therapy for acute renal transplant rejection.
Jeffrey RF; Johnson MH; Bamford JM; Giles GR; Brownjohn AM; Will EJ
Transplantation; 1993 Mar; 55(3):677-9. PubMed ID: 8456493
[No Abstract] [Full Text] [Related]
5. Rapid growth of cutaneous neuroendocrine (Merkel cell) carcinoma during treatment of refractory cardiac allograft rejection with OKT3 monoclonal antibody.
Stempfle HU; Mudra H; Angermann CE; Weiss M; Reichart B; Theisen K
J Heart Lung Transplant; 1993; 12(3):501-3. PubMed ID: 8329426
[TBL] [Abstract][Full Text] [Related]
6. OKT3 as prophylaxis immunosuppression in pediatric liver transplant recipients.
Sommerauer JF; Atkison P; Howard J; Grant D; Wall W
Transplant Proc; 1994 Feb; 26(1):154-6. PubMed ID: 8108917
[No Abstract] [Full Text] [Related]
7. Mouse antibody-coated lymphocytes during OKT3 therapy in liver transplantation.
Broughan TA; Valenzuela R; Escorcia E; Secic M; Vogt DP
Clin Transplant; 1994 Oct; 8(5):488-91. PubMed ID: 7819617
[TBL] [Abstract][Full Text] [Related]
8. [Differential diagnosis of transplant function disorders in therapy with monoclonal antibodies OKT3].
Müller T; Keuchel M; Schindler S; Steinmetz A; Feiber H; Lange H
Helv Chir Acta; 1991 Sep; 58(3):271-5. PubMed ID: 1769844
[TBL] [Abstract][Full Text] [Related]
9. Reduction of the initial febrile response to OKT3 with indomethacin.
First MR; Schroeder TJ; Hariharan S; Weiskittel P
Transplant Proc; 1993 Apr; 25(2 Suppl 1):52-4. PubMed ID: 8465426
[No Abstract] [Full Text] [Related]
10. OKT3 prophylaxis in kidney transplant recipients: drug monitoring by flow cytometry.
Cinti P; Cocciolo P; Evangelista B; Orlandini AM; Bruzzone P; Renna Molajoni E; Cortesini R
Transplant Proc; 1996 Dec; 28(6):3214-6. PubMed ID: 8962245
[No Abstract] [Full Text] [Related]
11. Consequences of anti-OKT3 antibody development: OKT3 reuse and long-term graft survival.
Shield CF
Transplant Proc; 1993 Apr; 25(2 Suppl 1):81-2. PubMed ID: 8465434
[No Abstract] [Full Text] [Related]
12. OKT3-induced cytokine-release syndrome: renal effects (cytokine nephropathy).
First MR; Schroeder TJ; Hariharan S
Transplant Proc; 1993 Apr; 25(2 Suppl 1):25-6. PubMed ID: 8465417
[No Abstract] [Full Text] [Related]
13. Nursing guidelines for muromonab-CD3 (OKT3).
Duffy MM; Nestor A
ANNA J; 1992 Oct; 19(5):493-5. PubMed ID: 1456797
[TBL] [Abstract][Full Text] [Related]
14. Treatment of steroid resistant rejection following renal transplantation: benefits and risks of OKT3 therapy.
Kehinde EO; Feehally J; Scriven SD; Veitch PS; Bell PR
Transplant Proc; 1996 Jun; 28(3):1449-50. PubMed ID: 8658735
[No Abstract] [Full Text] [Related]
15. Laboratory monitoring of therapy with OKT3 and other murine monoclonal antibodies.
Colvin RB; Preffer FI
Clin Lab Med; 1991 Sep; 11(3):693-714. PubMed ID: 1934971
[TBL] [Abstract][Full Text] [Related]
16. CD3 antigen modulation in T-lymphocytes during OKT3 treatment.
Magnussen K; Klug B; Møller B
Transplant Proc; 1994 Jun; 26(3):1731. PubMed ID: 8030108
[No Abstract] [Full Text] [Related]
17. Increased levels of sTNF receptors following OKT3 treatment.
Bemelman FJ; Jansen J; van der Poll T; Hack CE; van Deventer SJ; ten Berge RJ
Transplant Proc; 1994 Dec; 26(6):3094-5. PubMed ID: 7998082
[No Abstract] [Full Text] [Related]
18. Monoclonal antibodies in organ transplantation.
Valdés RH
Transplant Proc; 1996 Dec; 28(6):3293. PubMed ID: 8962277
[No Abstract] [Full Text] [Related]
19. Cytokine profiles in early rejection following OKT3 treatment in liver transplant patients.
Roayaie S; Sheiner PA; Emre S; Guy S; Schwartz ME; Boros P; Miller CM
Mediators Inflamm; 2000; 9(3-4):141-6. PubMed ID: 11132770
[TBL] [Abstract][Full Text] [Related]
20. Pentoxifylline reduces the first-dose reactions following OKT3.
Vincenti FG; Vasconcelos M; Birnbaum JL; Tomlanovich SJ; Amend WJ; Melzer JS; Snyder JP
Transplant Proc; 1993 Apr; 25(2 Suppl 1):57-9. PubMed ID: 8465428
[No Abstract] [Full Text] [Related]
[Next] [New Search]
